Summary Thirty-four cases of ductal carcinoma in situ (DCIS) of the breast, with or without associated benign or invasive disease, were anlaysed for allelic imbalance (Al) 
Mutations of the BRCA1 gene on chromosome 17q21 are thought to be responsible for a proportion of inherited breast cancers . Many of the other tumoursuppressor genes originally identified as a result of their involvement in familial cancers are known to be mutated in sporadic tumours. There has, therefore, been much interest in the involvement of BRCAJ in sporadic forms of breast cancer. Loss of heterozygosity (LOH), which suggests the inactivation of a tumour-suppressor gene (Ponder, 1988) , has been demonstrated in the vicinity of the BRCAI locus in breast tumours by a number of groups (Futreal et al., 1992; Cornelis et al., 1993; Cropp et al., 1993; Borg et al., 1994) . However, the majority of the cases studied have been invasive tumours, and the involvement of the BRCAJ gene in the earlier stages of sporadic breast tumour development has not yet been specifically addressed.
The analysis of early preinvasive lesions not only allows the identification of genetic alterations that might be initiating events in tumorigenesis, but, when compared with alterations occurring in invasive carcinoma from the same patient, allows important conclusions to be drawn regarding the stepwise progression of breast tumours. The relationship between preinvasive breast lesions and invasive carcinoma is at present unclear. Epidemiological studies have shown that patients with atypical epithelial hyperplasia and with carcinoma in situ are at increased risk of developing invasive breast cancer (Rosen et al., 1980; Dupont and Page, 1985; Tavassoli and Norris, 1990) . In particular, patients with ductal carcinoma in situ (DCIS) have a substantial risk, and circumstantial evidence suggests that it may be a precursor lesion (Betsill et al., 1978; Page et al., 1982) . There is little molecular data regarding the nature of DCIS, as genetic analysis is mainly restricted to tumour material microdissected from paraffin-embedded tissue sections. However, we and others have demonstrated that a number of genetic alterations occurring in invasive carcinomas are also present in DCIS, namely c-erbB-2 amplification, TP53 mutation and allelic loss on chromosomes 1, 7, 16 and 17p (Liu et al., 1992; Radford et al., 1993; Munn et al., 1995 Munn et al., , 1996 Stratton et al., 1995) . In this present study we (1992) and Cornelis et al. (1993) respectively. In addition intragenic TP53 polymorphisms and polymorphisms at 17pl3.3 were used to control for allele loss on chromosome 17p, as described by Munn et al. (1996) . Normal and tumour DNA were analysed as previously described by Munn et al. (1995) , except that the amplification conditions were as follows: 4 min at 94°C followed by 35 cycles of 1 min at 94°C, 1 min at 55°C, 1 min at 72°C, and a final extension at 72°C for 10 min. Allelic imbalance (Al) was determined in heterozygotes as a reduction in intensity of one allele relative to the other in the tumour sample according to criteria described by Hoggard et al. (1995) . The data were confirmed by analysing the dried gels using a phosphorimager (Molecular Dynamics 425S). Table II ). breast tumours to date , although there are recent reports of mutations in sporadic ovarian tumours (Merajver et al., 1995 NM23 and PHB (prohibitin) (Leone et al., 1991; Sato et al., 1992; Royds et al., 1993) , alterations to both of which have been previously demonstrated in sporadic breast tumours. In addition the c-erbB-2 gene maps between Dl 7S250 and D17S579. Overexpression of c-erbB-2 has frequently been observed in breast tumours and this is generally thought to be due to gene amplification. A number of the cases of DCIS showing Al at the BRCA I region in this study have previously been shown to overexpress c-erbB-2 (R Walker, unpublished). However, the patterns of Al observed in these tumours were suggestive of allele loss rather than gain. Therefore, if c-erbB-2 is amplified in these cases the amplicon must be on the remaining homologue, indicating the presence of multiple alterations on chromosome 17q in these cases. In addition, two cases were found to show Al at a region independent from BRCAJ, suggesting a second tumoursuppressor gene on 17q. This has been reported previously by several groups (Cornelis et al., 1993; Cropp et al., 1993) . The finding that 12 out of 18 cases with both DCIS and invasive tumour show the same pattern of Al in each component suggests that DCIS can progress to invasive carcinoma. That this is not the case for all DCIS is clear from those cases showing distinct alterations in both components. This is complicated further by the heterogeneity present within DCIS. Whatever the target of the Al observed in this study, it is clear from those cases with DCIS and invasive components that its alteration can occur early or late in the development of breast tumours.
Four of the cases reported here contained benign lesions (1565, 2996, 6045 and 6457), and two of these showed Al on 17q. In neither case was Pagetoid spread considered a possibility, and in both cases only epithelial cells were analysed. In case 6457 (fibroadenosis + comedo DCIS + invasive tumour) the same pattern of Al was seen in all three components. However in 6045, Al was only observed in the papilloma and not in the invasive cells (DCIS cells were not present on the sections made available to us and were therefore not studied). The finding of a case that shows Al in a papilloma but not in the associated invasive tumour questions the importance of changes to sequences on 17q for malignant transformation. Alterations to 17q present in the later stages of tumour development might contribute to malignancy by co-operating with other changes such as TP53 mutations. Their role in benign lesions remains to be elucidated.
